denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: MDS Foundation, Inc.
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
aplasia, AML, Biological, Adult, Diseases, aplastic anemia, drug-drug interaction, Non-Biological, Diamond Blackfan Anemia, Bone Marrow Failure, Therapies, CAR-Ts, Elderly, Fanconi Anemia, MDS, checkpoint inhibitors, chemotherapy, iron deficiency, enzyme inhibitors, PNH, Study Population, Myeloid Malignancies, Clinically relevant
Hematology Disease Topics & Pathways:
aplasia, AML, Biological, Adult, Diseases, aplastic anemia, drug-drug interaction, Non-Biological, Diamond Blackfan Anemia, Bone Marrow Failure, Therapies, CAR-Ts, Elderly, Fanconi Anemia, MDS, checkpoint inhibitors, chemotherapy, iron deficiency, enzyme inhibitors, PNH, Study Population, Myeloid Malignancies, Clinically relevant
Friday, December 4, 2020: 7:00 AM-10:00 AM
Chair:
Mario Cazzola, Fondazione IRCCS Policlinico San Matteo
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Jane E. Churpek, MD, MS, University of Wisconsin School of Medicine and Public Health
,
Rafael Bejar, MD, PhD, University of California, San Diego
,
Amy E. DeZern, MD, Johns Hopkins University School of Medicine
,
Katharina S. Götze, Technical University of Munich
,
Saar I. Gill, MD, PhD, University of Pennsylvania
and
Stephane De Botton, MD, PhD, Institut Gustave Roussy
Disclosures:
Churpek: UpToDate, Inc.: Honoraria. Bejar: Astex/Otsuka: Honoraria; Daiichi-Sankyo: Honoraria; Forty-Seven/Gilead: Honoraria; Genoptix/NeoGenomics: Honoraria; AbbVie/Genentech: Honoraria; Aptose Biosciences: Current Employment; Celgene/BMS: Honoraria, Research Funding; Takeda: Honoraria, Research Funding. DeZern: MEI: Consultancy; Abbvie: Consultancy; Astex: Research Funding; Celgene: Consultancy, Honoraria. Götze: Celgene: Research Funding. Gill: Tmunity: Research Funding; Carisma Therapeutics: Research Funding; Carisma Therapeutics: Current equity holder in private company; Interius Biotherapeutics: Current equity holder in private company; Novartis: Research Funding. De Botton: Pierre Fabre: Consultancy; Novartis: Consultancy; Pfizer: Consultancy; Servier: Consultancy; Daiichi Sankyo: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Forma Therapeutics: Honoraria, Research Funding; Agios: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Speakers Bureau; Syros: Consultancy, Honoraria; Seattle Genetics: Honoraria; Bayer: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria.
Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).
Topics will include:
Challenges in MDS Diagnosis
Managing MDS in the Wake of a Global Pandemic
Venetoclax in Higher-Risk MDS/AML
Role of CAR-T Cells in Myeloid Malignancies: Lessons Learned from Lymphoid Malignancies
Targeted Therapies (enasidenib, ivosidenib, APR-246)
See more of: Satellite Symposia